Natriuretic peptides and other biomarkers in chronic heart failure: From BNP, NT-proBNP, and MR-proANP to routine biochemical markers

被引:59
作者
Lainscak, Mitja [1 ,2 ]
von Haehling, Stephan [2 ,3 ]
Anker, Stefan D. [2 ,3 ]
机构
[1] Univ Clin Resp & Allerg Dis, Div Cardiol, SI-4204 Golnik, Slovenia
[2] Charite Univ Med Berlin, Campus Virchow Clin, Dept Cardiol, Div Appl Cachexia Res, Berlin, Germany
[3] Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Clin Cardiol, London, England
关键词
Cachexia; Cholesterol; Hemoglobin; Heart failure; Natriuretic peptides; Uric acid; TUMOR-NECROSIS-FACTOR; LEFT-VENTRICULAR FUNCTION; URIC-ACID; EXERCISE TOLERANCE; INSULIN-RESISTANCE; FACTOR-ALPHA; CYSTATIN-C; DARBEPOETIN-ALPHA; IMMUNE ACTIVATION; XANTHINE-OXIDASE;
D O I
10.1016/j.ijcard.2008.11.149
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Cardiac biomarkers play an important role in heart failure. The family of natriuretic peptides, especially B-type natriuretic peptide, was identified as a valued diagnostic and prognostic tool. Not unexpectedly, the natriuretic peptides fail to fulfill all the criteria of an ideal biochemical marker. The quest for a single marker or a combination is therefore still on and several established, widely available biomarkers might have been overlooked in the field of heart failure. This review puts forward some of those biomarkers, and we speculate on the possible roles of combining two or more biomarkers. In that sense, any blood parameter including hemoglobin, cholesterol, uric acid, and recently identified proteins might function as a biomarker. Additionally, several biomarkers are discussed and we try to anticipate their diagnostic and prognostic value along with the natriuretic peptides and established biomarkers. Finally, we speculate about the potential of sharing the biomarkers over a variety of chronic diseases with similar pathophysiology. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:303 / 311
页数:9
相关论文
共 103 条
[1]
MOLECULAR-CLONING AND SEQUENCE-ANALYSIS OF CDNA CODING FOR THE PRECURSOR OF THE HUMAN CYSTEINE PROTEINASE-INHIBITOR CYSTATIN-C [J].
ABRAHAMSON, M ;
GRUBB, A ;
OLAFSSON, I ;
LUNDWALL, A .
FEBS LETTERS, 1987, 216 (02) :229-233
[2]
STRUCTURE AND EXPRESSION OF THE HUMAN CYSTATIN-C GENE [J].
ABRAHAMSON, M ;
OLAFSSON, I ;
PALSDOTTIR, A ;
ULVSBACK, M ;
LUNDWALL, A ;
JENSSON, O ;
GRUBB, A .
BIOCHEMICAL JOURNAL, 1990, 268 (02) :287-294
[3]
Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume [J].
Adlbrecht, Christopher ;
Kommata, Spyridoula ;
Huelsmann, Martin ;
Szekeres, Thomas ;
Bieglmayer, Christian ;
Strunk, Guido ;
Karanikas, Georgios ;
Berger, Rudolf ;
Moertl, Deddo ;
Kletter, Kurt ;
Maurer, Gerald ;
Lang, Irene M. ;
Pacher, Richard .
EUROPEAN HEART JOURNAL, 2008, 29 (19) :2343-2350
[4]
Atrial natriuretic peptide and related peptides [J].
Akashi, Yoshihiro J. ;
Springer, Jochen ;
Lainscak, Mitja ;
Anker, Stefan D. .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (10) :1259-1267
[5]
Neurohumoral activation as a link to systemic manifestations of chronic lung disease [J].
Andreas, S ;
Anker, SD ;
Scanlon, PD ;
Somers, VK .
CHEST, 2005, 128 (05) :3618-3624
[6]
Metabolic, functional, and haemodynamic staging for CHF? [J].
Anker, SD ;
Coats, AJS .
LANCET, 1996, 348 (9041) :1530-1531
[7]
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study [J].
Anker, SD ;
Negassa, A ;
Coats, AJS ;
Afzal, R ;
Poole-Wilson, PA ;
Cohn, JN ;
Yusuf, S .
LANCET, 2003, 361 (9363) :1077-1083
[8]
Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].
Anker, SD ;
Doehner, W ;
Rauchhaus, M ;
Sharma, R ;
Francis, D ;
Knosalla, C ;
Davos, CH ;
Cicoira, M ;
Shamim, W ;
Kemp, M ;
Segal, R ;
Osterziel, KJ ;
Leyva, F ;
Hetzer, R ;
Ponikowski, P ;
Coats, AJS .
CIRCULATION, 2003, 107 (15) :1991-1997
[9]
Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure [J].
Anker, SD ;
Leyva, F ;
PooleWilson, PA ;
Kox, WJ ;
Stevenson, JC ;
Coats, AJS .
HEART, 1997, 78 (01) :39-43
[10]
Insights into the pathogenesis of chronic heart failure: immune activation and cachexia [J].
Anker, SD ;
Rauchhaus, M .
CURRENT OPINION IN CARDIOLOGY, 1999, 14 (03) :211-216